Cargando…

Identification of Early Biochemical Recurrence Predictors in High-Risk Prostate Cancer Patients Treated with Carbon-Ion Radiotherapy and Androgen Deprivation Therapy

The aim of this retrospective study was to identify clinical predictors of early biochemical recurrence (BCR) in patients with high-risk prostate cancer (PCa) treated with carbon-ion radiotherapy (CIRT) and androgen deprivation therapy (ADT). A total of 670 high-risk PCa patients treated with CIRT a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Utsumi, Takanobu, Suzuki, Hiroyoshi, Ishikawa, Hitoshi, Wakatsuki, Masaru, Okonogi, Noriyuki, Harada, Masaoki, Ichikawa, Tomohiko, Akakura, Koichiro, Murakami, Yoshitaka, Tsuji, Hiroshi, Yamada, Shigeru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605605/ https://www.ncbi.nlm.nih.gov/pubmed/37887536 http://dx.doi.org/10.3390/curroncol30100636

Ejemplares similares

Safety and Efficacy of Carbon-Ion Radiotherapy for Elderly Patients with High-Risk Prostate Cancer
por: Hiroshima, Yuichi, et al.
Publicado: (2022)

Cancer‐specific mortality of high‐risk prostate cancer after carbon‐ion radiotherapy plus long‐term androgen deprivation therapy
por: Kasuya, Goro, et al.
Publicado: (2017)

Significant impact of biochemical recurrence on overall mortality in patients with high‐risk prostate cancer after carbon‐ion radiotherapy combined with androgen deprivation therapy
por: Kasuya, Goro, et al.
Publicado: (2016)

Carbon‐ion radiotherapy for urological cancers
por: Ishikawa, Hitoshi, et al.
Publicado: (2022)

Worsening of the low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio in patients with prostate cancer after androgen deprivation therapy
por: Oka, Ryo, et al.
Publicado: (2018)

Intermittent Androgen Suppression: Estimating Parameters for Individual Patients Based on Initial PSA Data in Response to Androgen Deprivation Therapy
por: Hirata, Yoshito, et al.
Publicado: (2015)

Five-year quality of life assessment after carbon ion radiotherapy for prostate cancer
por: Maruyama, Katsuya, et al.
Publicado: (2017)

Risk of secondary malignancy after radiotherapy for breast cancer: long-term follow-up of Japanese patients with breast cancer
por: Okonogi, Noriyuki, et al.
Publicado: (2022)

Secondary cancers after carbon‐ion radiotherapy and photon beam radiotherapy for uterine cervical cancer: A comparative study
por: Nitta, Yuki, et al.
Publicado: (2022)

Optimal Androgen Deprivation Therapy Combined with Proton Beam Therapy for Prostate Cancer: Results from a Multi-Institutional Study of the Japanese Radiation Oncology Study Group
por: Murakami, Motohiro, et al.
Publicado: (2020)

The clinical relative biological effectiveness and prostate‐specific antigen kinetics of carbon‐ion radiotherapy in low‐risk prostate cancer
por: Kang, Yu‐Mei, et al.
Publicado: (2022)

Clinical advantage and outcomes of computed tomography‐based transvaginal hybrid brachytherapy performed only by sedation without general or saddle block anesthesia
por: Okonogi, Noriyuki, et al.
Publicado: (2022)

Personalizing Androgen Suppression for Prostate Cancer Using Mathematical Modeling
por: Hirata, Yoshito, et al.
Publicado: (2018)

Dose constraints in the rectum and bladder following carbon-ion radiotherapy for uterus carcinoma: a retrospective pooled analysis
por: Okonogi, Noriyuki, et al.
Publicado: (2018)

Multi-Institutional Retrospective Analysis of Carbon-Ion Radiotherapy for Patients with Locally Advanced Adenocarcinoma of the Uterine Cervix
por: Okonogi, Noriyuki, et al.
Publicado: (2021)

Treatment strategy for metastatic prostate cancer with extremely high PSA level: reconsidering the value of vintage therapy
por: Yamada, Yasutaka, et al.
Publicado: (2018)

Significance of concurrent use of weekly cisplatin in carbon‐ion radiotherapy for locally advanced adenocarcinoma of the uterine cervix: A propensity score‐matched analysis
por: Okonogi, Noriyuki, et al.
Publicado: (2019)

Complications, Urinary Continence, and Oncologic Outcomes of Laparoscopic Radical Prostatectomy: Single-Surgeon Experience for the First 100 Cases
por: Imamoto, Takashi, et al.
Publicado: (2011)

Impact of Lymphovascular Invasion on Prognosis in the Patients with Bladder Cancer—Comparison of Transurethral Resection and Radical Cystectomy
por: Yoneda, Kei, et al.
Publicado: (2021)

Nomogram for predicting the biochemical recurrence of prostate cancer after neoadjuvant androgen deprivation therapy
por: Sun, Qi, et al.
Publicado: (2023)

Pretreatment PSA levels affects the completion rate of Ra-223 treatment
por: Utsumi, Nobuko, et al.
Publicado: (2021)

Author Correction: Pretreatment PSA levels affects the completion rate of Ra-223 treatment
por: Utsumi, Nobuko, et al.
Publicado: (2021)

Epigenetic Regulation of the KAI1 Metastasis Suppressor Gene in Human Prostate Cancer Cell Lines
por: Sekita, Nobuyuki, et al.
Publicado: (2001)

Expression of Thymidine Phosphorylase in Primary Human Renal Cell Carcinoma by ELISA Method
por: Kinsui, Hidetoshi, et al.
Publicado: (2002)

Risk factors for rectal bleeding associated with I-125 brachytherapy for prostate cancer
por: Harada, Kosaku, et al.
Publicado: (2012)

Better Understanding the Timing Of Androgen Deprivation Trial Outcomes: Impacts of Prior Androgen Deprivation Therapy
por: Stensland, Kristian D, et al.
Publicado: (2022)

Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer
por: Aggarwal, Rahul, et al.
Publicado: (2022)

Significant prognostic difference between Grade Group 4 and 5 in the 2014 International Society of Urological Pathology Grading System for High Grade Prostate Cancer with Bone Metastasis
por: Yamada, Yasutaka, et al.
Publicado: (2017)

Carbon-ion radiotherapy for inoperable endometrial carcinoma
por: Irie, Daisuke, et al.
Publicado: (2018)

Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma
por: Kawakita, Daisuke, et al.
Publicado: (2022)

The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment
por: Ku, Ja Yoon, et al.
Publicado: (2015)

Development and External Validation of a Nomogram Predicting the Probability of Significant Gleason Sum Upgrading among Japanese Patients with Localized Prostate Cancer
por: Imamoto, Takashi, et al.
Publicado: (2011)

Analysis of Preoperative Detection for Apex Prostate Cancer by Transrectal Biopsy
por: Sazuka, Tomokazu, et al.
Publicado: (2013)

A Phase Ib Study of Durvalumab (MEDI4736) in Combination with Carbon-Ion Radiotherapy and Weekly Cisplatin for Patients with Locally Advanced Cervical Cancer (DECISION Study): The Early Safety and Efficacy Results
por: Okonogi, Noriyuki, et al.
Publicado: (2023)

Machine-learning predicts time-series prognosis factors in metastatic prostate cancer patients treated with androgen deprivation therapy
por: Saito, Shinpei, et al.
Publicado: (2023)

Androgen deprivation and cognition in prostate cancer
por: Salminen, E, et al.
Publicado: (2003)

Androgen Deprivation Therapy and Cardiovascular Risk
por: Mourmouris, Panagiotis, et al.
Publicado: (2012)

Metabolic effects of androgen deprivation therapy
por: Choi, See Min, et al.
Publicado: (2015)

Cardiovascular Toxicities of Androgen Deprivation Therapy
por: Challa, Azariyas A., et al.
Publicado: (2021)

CARDIOVASCULAR DISEASES AND ANDROGEN DEPRIVATION THERAPY
por: Boban, Marko
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_638ntd54ujh4tfp3oq8fvr6ekg